Congress does not pass 'most favored nation' drug pricing into law by December 2026

PhRMA and industry CEOs have publicly opposed the policy, citing concerns over care rationing. Republican opposition in Congress and recent industry lobbying efforts reduce the likelihood of legislative passage.

Implied probability (Yes)

85%